<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04812678</url>
  </required_header>
  <id_info>
    <org_study_id>FF2021</org_study_id>
    <nct_id>NCT04812678</nct_id>
  </id_info>
  <brief_title>Efficacy of DBM Fasciatherapy for Patients Suffering From Chronic Low Back Pain</brief_title>
  <official_title>Interest of DBM Fasciatherapy for Physiotherapy in the Care of Patients Suffering From Non-Specific Chronic Low Back Pain: a Cluster Randomized Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FasciaFrance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Fernando Pessoa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FasciaFrance</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low back pain (LBP) is pain localized below the costal margin and above the inferior gluteal&#xD;
      folds. It may be associated with radiculalgia. Non-specific LBP refers to LBP without&#xD;
      specific problems such as infection, inflammation, vertebral fracture or cancer. Chronic LBP&#xD;
      is a LBP lasting more than 3 months.&#xD;
&#xD;
      The causes of LBP remain unknown. While there are recommendations for physiotherapy, the&#xD;
      protocol of care is not well defined. New therapeutic models centered on neurophysiology are&#xD;
      replacing biomechanics-based models. New programs centered on patient education and a&#xD;
      biopsychosocial approach are emerging.&#xD;
&#xD;
      Research has shown the possible involvement of fascia in LBP and the interest of manual&#xD;
      fascia therapies in the treatment of LBP. To date, there are no studies that have shown the&#xD;
      effects of fasciatherapy in the treatment of non-specific LBP.&#xD;
&#xD;
      In France, many physiotherapists use this type of treatment and more specifically&#xD;
      fasciatherapy. French physiotherapists say that it may improve their management of LBP.&#xD;
      Studies on fasciatherapy have highlighted the effects of fasciatherapy in the management of&#xD;
      fibromyalgia pain, the treatment of anxiety, malaise and the improvement of body perception.&#xD;
      They show the multidimensional actions of fasciatherapy and support its clinical, functional&#xD;
      and psychosocial evaluation for LBP.&#xD;
&#xD;
      Fasciatherapy is part of the manual therapies that target their action on the fascial system.&#xD;
      This &quot;patient-centered&quot; technique is a biopsychosocial and humanistic approach to health. The&#xD;
      manual and gestural approaches of the fascia are part of the Non-Pharmaceutical Interventions&#xD;
      field. Fasciatherapy involves manual and gestural interventions, with the objective of&#xD;
      restoring the contractile, elastic and movement properties of the fascia in order to provide&#xD;
      relief, improve function and quality of life for patients.&#xD;
&#xD;
      In France, fasciatherapy is not part of recommendations and is not recognized by the Conseil&#xD;
      National de l'Ordre des Masseurs-Kinésithérapeutes.&#xD;
&#xD;
      This study aims to assess the effects of fasciatherapy on LBP and to evaluate how it could&#xD;
      contribute to its management for physiotherapists. It is a cluster randomized trial conducted&#xD;
      on 180 subjects. Intensity of pain (measured with VAS) is the primary outcome. The secondary&#xD;
      outcomes are the impact of LBP on daily life (Dallas Pain Questionnaire), on quality of life&#xD;
      (SF-12 questionnaire), on anxiety (STAI questionnaire), and the evolution of drug&#xD;
      consumption.&#xD;
&#xD;
      The study will take place in France and the treatment structures will be the practitioners'&#xD;
      practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>Before the 1st session (start of the study for the patient)</time_frame>
    <description>Measure of pain intensity with Visual Analog Scale: 0 (no pain) to 10 (worst imaginable pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>After the 1st session (30 to 45 minutes after the previous measure)</time_frame>
    <description>Measure of pain intensity with Visual Analog Scale: 0 (no pain) to 10 (worst imaginable pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>Before the 2nd session (within a total timeframe of 3 months)</time_frame>
    <description>Measure of pain intensity with Visual Analog Scale: 0 (no pain) to 10 (worst imaginable pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>After the 2nd session (30 to 45 minutes after the previous measure)</time_frame>
    <description>Measure of pain intensity with Visual Analog Scale: 0 (no pain) to 10 (worst imaginable pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>Before the 3rd session (within a total timeframe of 3 months)</time_frame>
    <description>Measure of pain intensity with Visual Analog Scale: 0 (no pain) to 10 (worst imaginable pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>After the 3rd session (30 to 45 minutes after the previous measure)</time_frame>
    <description>Measure of pain intensity with Visual Analog Scale: 0 (no pain) to 10 (worst imaginable pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>Before the 4th session (within a total timeframe of 3 months)</time_frame>
    <description>Measure of pain intensity with Visual Analog Scale: 0 (no pain) to 10 (worst imaginable pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>After the 4th session (30 to 45 minutes after the previous measure)</time_frame>
    <description>Measure of pain intensity with Visual Analog Scale: 0 (no pain) to 10 (worst imaginable pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>Before the 5th session (within a total timeframe of 3 months)</time_frame>
    <description>Measure of pain intensity with Visual Analog Scale: 0 (no pain) to 10 (worst imaginable pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>After the 5th session (30 to 45 minutes after the previous measure)</time_frame>
    <description>Measure of pain intensity with Visual Analog Scale: 0 (no pain) to 10 (worst imaginable pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in functional abilities</measure>
    <time_frame>Before the 1st session and after the last (5st) session, in a timeframe of 3 months</time_frame>
    <description>Evaluation of the functional disability change, with French version of Dallas Pain Questionnaire: 4 items evaluated from 0 (no impact) to 100% (maximun impact)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the quality of life</measure>
    <time_frame>Before the 1st session and after the last (5st) session, in a timeframe of 3 months</time_frame>
    <description>Assessment of the change in the quality of life with the French version of the short version (SF-12) of &quot;Short Form with 36 questions&quot; (SF-36) questionnaire: scale from 0 (bad) to 100 (best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in trait of anxiety</measure>
    <time_frame>Before the 1st session and after the last (5st) session, in a timeframe of 3 months</time_frame>
    <description>Evaluation of the change in trait of anxiety with State Trait Inventory Anxiety questionnaire, part Y-B: scale from 20 (no anxiety) to 80 (maximum anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of state of anxiety</measure>
    <time_frame>Before the 1st session (start of the study for the patient)</time_frame>
    <description>Evaluation of the change in state of anxiety with State Trait Inventory Anxiety questionnaire, part Y-A: scale from 20 (no anxiety) to 80 (maximum anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of state of anxiety</measure>
    <time_frame>After the 1st session (30 to 45 minutes after the previous measure)</time_frame>
    <description>Evaluation of the change in state of anxiety with State Trait Inventory Anxiety questionnaire, part Y-A: scale from 20 (no anxiety) to 80 (maximum anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of state of anxiety</measure>
    <time_frame>Before the 2nd session (within a total timeframe of 3 months)</time_frame>
    <description>Evaluation of the change in state of anxiety with State Trait Inventory Anxiety questionnaire, part Y-A: scale from 20 (no anxiety) to 80 (maximum anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of state of anxiety</measure>
    <time_frame>After the 2nd session (30 to 45 minutes after the previous measure)</time_frame>
    <description>Evaluation of the change in state of anxiety with State Trait Inventory Anxiety questionnaire, part Y-A: scale from 20 (no anxiety) to 80 (maximum anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of state of anxiety</measure>
    <time_frame>Before the 3rd session (within a total timeframe of 3 months)</time_frame>
    <description>Evaluation of the change in state of anxiety with State Trait Inventory Anxiety questionnaire, part Y-A: scale from 20 (no anxiety) to 80 (maximum anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of state of anxiety</measure>
    <time_frame>After the 3rd session (30 to 45 minutes after the previous measure)</time_frame>
    <description>Evaluation of the change in state of anxiety with State Trait Inventory Anxiety questionnaire, part Y-A: scale from 20 (no anxiety) to 80 (maximum anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of state of anxiety</measure>
    <time_frame>Before the 4th session (within a total timeframe of 3 months)</time_frame>
    <description>Evaluation of the change in state of anxiety with State Trait Inventory Anxiety questionnaire, part Y-A: scale from 20 (no anxiety) to 80 (maximum anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of state of anxiety</measure>
    <time_frame>After the 4th session (30 to 45 minutes after the previous measure)</time_frame>
    <description>Evaluation of the change in state of anxiety with State Trait Inventory Anxiety questionnaire, part Y-A: scale from 20 (no anxiety) to 80 (maximum anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of state of anxiety</measure>
    <time_frame>Before the 5th session (within a total timeframe of 3 months)</time_frame>
    <description>Evaluation of the change in state of anxiety with State Trait Inventory Anxiety questionnaire, part Y-A: scale from 20 (no anxiety) to 80 (maximum anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of state of anxiety</measure>
    <time_frame>After the 5th session (30 to 45 minutes after the previous measure)</time_frame>
    <description>Evaluation of the change in state of anxiety with State Trait Inventory Anxiety questionnaire, part Y-A: scale from 20 (no anxiety) to 80 (maximum anxiety)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug consumption</measure>
    <time_frame>1st session (start of the study for the patient)</time_frame>
    <description>Evaluation of drug consumption (interview of the patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug consumption</measure>
    <time_frame>2nd session (within a total timeframe of 3 months)</time_frame>
    <description>Evaluation of drug consumption (interview of the patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug consumption</measure>
    <time_frame>3rd session (within a total timeframe of 3 months)</time_frame>
    <description>Evaluation of drug consumption (interview of the patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug consumption</measure>
    <time_frame>4th session (within a total timeframe of 3 months)</time_frame>
    <description>Evaluation of drug consumption (interview of the patient)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug consumption</measure>
    <time_frame>5th session (within a total timeframe of 3 months)</time_frame>
    <description>Evaluation of drug consumption (interview of the patient)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Physiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional physiotherapy, in line with french &quot;Haute Autorité de Santé&quot; guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiotherapy and Fasciatherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional physiotherapy, in line with french &quot;Haute Autorité de Santé&quot; guidelines, associated with Fasciatherapy Danis Bois Method</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fasciatherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fasciatherapy Danis Bois Method</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fasciatherapy</intervention_name>
    <description>Fasciatherapy, with manual therapy and/or gestual therapy.</description>
    <arm_group_label>Fasciatherapy</arm_group_label>
    <arm_group_label>Physiotherapy and Fasciatherapy</arm_group_label>
    <other_name>DBM Fasciatherapy</other_name>
    <other_name>Danis Bois Method Fasciatherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physiotherapy</intervention_name>
    <description>Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.</description>
    <arm_group_label>Physiotherapy</arm_group_label>
    <arm_group_label>Physiotherapy and Fasciatherapy</arm_group_label>
    <other_name>Physical Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  First consultation for Low Back Pain with the practitioner&#xD;
&#xD;
          -  Having a diagnostic of chronic non-specific Low Back Pain based on the French Haute&#xD;
             Autorité de Santé guidelines&#xD;
             (https://www.has-sante.fr/upload/docs/application/pdf/2019-04/fm_lombalgie_v2_2.pdf):&#xD;
&#xD;
          -  excluding specific Low Back Pain (tumor, infection, inflammation, etc.)&#xD;
&#xD;
          -  no red flag&#xD;
&#xD;
          -  Low Back Pain for more than 3 months&#xD;
&#xD;
          -  Having had the French validated version of:&#xD;
&#xD;
          -  evaluation of pain intensity with Visual Analog Scale&#xD;
&#xD;
          -  STarT Back Screening Tool questionnaire&#xD;
&#xD;
          -  Dallas Pain questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Specific Low Back Pain (rheumatologist disease, tumoral compression, central&#xD;
             neurological pathology, etc.)&#xD;
&#xD;
          -  Psychiatric disorder (apart from the usual co-morbidities of chronic low back pain)&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Being under guardianship or curatorship&#xD;
&#xD;
          -  Deprivation of liberty or legal protection measure&#xD;
&#xD;
          -  Being unable to give consent&#xD;
&#xD;
          -  Being unable of fill out a questionnaire&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Courraud, PhD, PT</last_name>
    <role>Study Director</role>
    <affiliation>Centre d'Etude et de Recherche Appliquée en Psychopédagogie perceptive - University Fernando Pessoa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cyril Dupuis, Ms, PT</last_name>
    <phone>+33473550055</phone>
    <email>cyril.h.dupuis@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Bertrand, PhD, PT</last_name>
    <email>isabelle.bertrand@cerap.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FasciaFrance</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Bertrand, PhD, PT</last_name>
      <email>isabelle.bertrand@cerap.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.has-sante.fr/upload/docs/application/pdf/2019-04/fm_lombalgie_v2_2.pdf</url>
    <description>French Haute Autorité de Santé guidelines for the treatment of non-specific Low Back Pain</description>
  </link>
  <reference>
    <citation>Bruyère O, Demoulin M, Beaudart C, Hill JC, Maquet D, Genevay S, Mahieu G, Reginster JY, Crielaard JM, Demoulin C. Validity and reliability of the French version of the STarT Back screening tool for patients with low back pain. Spine (Phila Pa 1976). 2014 Jan 15;39(2):E123-8. doi: 10.1097/BRS.0000000000000062.</citation>
    <PMID>24108286</PMID>
  </reference>
  <reference>
    <citation>Marty M, Blotman F, Avouac B, Rozenberg S, Valat J-P. Validation de la version française de l'échelle de Dallas chez les patients lombalgiques chroniques. Revue du rhumatisme (Ed française). 1998;65(2):139-47.</citation>
  </reference>
  <reference>
    <citation>Leplège A, Ecosse E, Verdier A, Perneger TV. The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol. 1998 Nov;51(11):1013-23.</citation>
    <PMID>9817119</PMID>
  </reference>
  <reference>
    <citation>Lawlis GF, Cuencas R, Selby D, McCoy CE. The development of the Dallas Pain Questionnaire. An assessment of the impact of spinal pain on behavior. Spine (Phila Pa 1976). 1989 May;14(5):511-6.</citation>
    <PMID>2524890</PMID>
  </reference>
  <reference>
    <citation>Ware J, Kolinski M, Keller S. How to score the SF-12 physical and mental health summaries: a user's manual. Boston: The Health Institute, New England Medical Centre, Boston, MA. 1995;</citation>
  </reference>
  <reference>
    <citation>Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain. 1983 May;16(1):87-101. doi: 10.1016/0304-3959(83)90088-X.</citation>
    <PMID>6602967</PMID>
  </reference>
  <reference>
    <citation>Boureau F. L'appréciation de la sévérité d'une douleur chronique. Médecine et hygiène. 1987;45(1703):1560-6.</citation>
  </reference>
  <reference>
    <citation>Wilke J, Schleip R, Klingler W, Stecco C. The Lumbodorsal Fascia as a Potential Source of Low Back Pain: A Narrative Review. Biomed Res Int. 2017;2017:5349620. doi: 10.1155/2017/5349620. Epub 2017 May 11. Review.</citation>
    <PMID>28584816</PMID>
  </reference>
  <reference>
    <citation>Courraud C, Bois D, Lieutaud A. Apports de la pratique de la fasciathérapie à l'exercice de la physiothérapie: le point de vue des praticiens. Mains Libres. 2016;(3):49-58.</citation>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Back Pain</keyword>
  <keyword>DBM Fasciatherapy</keyword>
  <keyword>Physiotherapy</keyword>
  <keyword>Manual Therapy</keyword>
  <keyword>Fascia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

